REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
 
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Five-membered Hetero Ring Containing At Least One Nitrogen Ring Atom (e.g., 1,2,3-triazoles, Etc.) > The Five-membered Hetero Ring Consists Of One Nitrogen And Four Carbons The Five-membered Hetero Ring Consists Of One Nitrogen And Four CarbonsThe Five-membered Hetero Ring Consists Of One Nitrogen And Four Carbons patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027201 - Use of progesterone receptor modulators wherein R1, R2, R3, R4, R5, R6 and R7, are as defined herein, for contraception, hormone replacement therapy, synchronizing estrus, treating dysmenorrhea, treating dysfunctional uterine bleeding, treating uterine myometrial fibroids, treating endometriosis, treating benign prostatic hypertrophy, treating carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, pituitary, and meningioma, ... 11/16/06 - 20060258730 - Sulfonic acids, their derivatives and pharmaceutical compositions containing them Selected sulfonic acids, their derivatives and pharmaceutical compositions containing such compounds are useful in inhibiting the chernotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CX-CR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. ... 08/31/06 - 20060194862 - 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention ... 06/29/06 - 20060142369 - Delta 1-pyrrolines used as pesticides R1, R2, R3, A, R4 and m have the meanings given in the description, a number of processes for preparing these substances and their use for controlling pests, and also novel intermediates and their preparation. ... 06/15/06 - 20060128779 - Control of parasites in animals by the use of parasiticidal 2-phenyl-3-(1h-pyrrol-2-yl)acrylonitrile derivatives 2-Phenyl-3-(1H-pyrrol-2-yl)acrylonitrile compounds useful for controlling parasites in animals and methods of treatment of parasite infestation in animals using the compounds are disclosed. ... 05/11/06 - 20060100261 - Furan or thiopene derivative and medicinal use thereof [wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, p is 0, 1 or 2, and when p is 2, each R may be the same or different, R1 is a hydrogen atom or an optionally substituted hydrocarbon group, R2 is an optionally substituted aromatic ... 04/06/06 - 20060074123 - Cyclic amp-specific phosphodiesterase inhibitors Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed. ... 03/23/06 - 20060063820 - 2,6-dihalo-4-(3,3-dichloro-allyloxy)-benzylalcohole derivatives having insecticidal and acaricidal properties Compounds of formula (I), wherein A1 is, for example, a bond or a C1-C6alkylene bridge; A2 is, for example, a bond or C1-C6alkylene; A3 is, for example, C1-C6alkylene; W is, for example, O or S; T is, for example, a bond, O, NH, NR7, S, SO, SO2, —C(═O)—O— or —O—C(═O)—; ... 01/12/06 - 20060009507 - Lpa receptor agonists and antagonists and methods of use The present invention relates to compounds according to formula (I) as disclosed herein as well as pharmaceutical compositions which include those compounds. Also disclosed are methods of using such compounds, which have activity as agonists or as antagonists of LPA receptors; such methods including inhibiting LPA activity on an LPA ... 01/05/06 - 20060004078 - N-hydroxyformamidine derivatives The present invention aims to provide an agent for inhibiting 20-HETE-producing enzymes, 20-HETE being involved in the effects of causing microvascular constriction or dilation in major organs (e.g., kidneys, cerebral blood vessels) or of inducing cell proliferation, etc. ... 01/05/06 - 20060004077 - Immunosuppressant compounds, methods and uses related thereto The present invention relates to compositions and methods for suppressing an immune response, e.g., by inhibiting class II MHC-mediated activation of T cells. The subject compounds and methods may be used to treat or prevent disorders such as rheumatoid arthritis and/or multiple sclerosis. ... 12/15/05 - 20050277688 - Crystalline form of a substituted pyrrolidine compound The invention provides a crystalline naphthalene-1,5-disulfonic acid salt of 2-[(S)-1-(8-methylaminooctyl)pyrrolidin-3-yl]-2,2-diphenylacetamide or a solvate thereof. This invention also provides pharmaceutical compositions comprising the salt or prepared using the salt; processes and intermediates for preparing the salt; and methods of using the salt to treat a pulmonary disorder. ... 11/24/05 - 20050261354 - Compositions and treatments for inhibiting kinase and/or hmg-coa reductase The present invention provides compositions of matter, kits and methods for their use in the treatment of MAP kinase-related conditions and/or HMG-CoA reductase-related conditions. In particular, the invention provides compositions for treating inflammatory and/or cardiovascular conditions in an animal subject by inhibiting p38α MAP kinase and/or HMG-CoA reductase, as well ... 10/27/05 - 20050239862 - Amino ceramide-like compounds and therapeutic methods of use Novel amino ceramide-like compounds (1) are provided which inhibit glucosyl ceramide (GlcCer) formation by inhibiting the enzyme GlcCer synthase, thereby lowering the level of glycosphingolipids. The compounds of the present invention have improved GlcCer synthase inhibition activity and are therefore highly useful in therapeutic methods for treating various conditions and ... 10/27/05 - 20050239861 - Medicinal composition The present invention relates to an ameliorant for improving the movement of the digestive tract comprising, as an active ingredient, 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-2-hydroxymethyl-4-pirrolidinyl]benzamide or an acid addition salt thereof which is a metabolite of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl]benzamide or an acid addition salt thereof, having high biding affinity for a serotonin receptor 4 (5HT4) and ... 09/15/05 - 20050203161 - Diphenylmethyl compounds useful as muscarinic receptor antagonists wherein a, b, c, e, m, R1, R2, R3, R4a, R4b, R5, R6, R7 and R8are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using ... 08/25/05 - 20050187280 - Furosemide modulators of hm74 Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula: ... 08/11/05 - 20050176800 - Pyrrolidine derivatives as prostaglandin modulators Substituted pyrrolidine compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or ... 08/04/05 - 20050171181 - Histamine-3 receptor modulators as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by modulating histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound ... 07/14/05 - 20050154043 - Heterocyclic compounds useful as growth hormone secretagogues The present invention relates to novel heterocyclic compounds, according to Formula I, that stimulate endogenous production and/or release of growth hormone, wherein R1, R2, R3, R4 and X are defined herein. Further, the present invention relates to methods for using such compounds and to pharmaceutical compositions containing such compounds. ... 07/14/05 - 20050154042 - N-alkyl pyrroles as hmg-coa reductase inhibitors HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided. ... 06/09/05 - 20050124679 - Alpha, beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors Disclosed are agents that inhibit histone deacetylase. More specifically, the present invention relates to novel hydroxamic acid derivatives or pharmaceutically acceptable salts thereof for anticancer agents or other therapeutic agents based on their histone deacetylase inhibitory activity. ... ### FreshPatents.com Support - Terms & Conditions |